Possible use of amantadine in depression

Pharmacopsychiatry

Volumn 32, Issue 2, 1999, Pages 47-55

  Huber, T J ^a   Dietrich, D E ^a   Emrich, H M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMANTADINE; AMPHETAMINE; ANTIDEPRESSANT AGENT; BETA ENDORPHIN; BETA LIPOTROPIN; BIOGENIC AMINE; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; LEVODOPA; MONOAMINE OXIDASE A INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORADRENALIN; PLACEBO; SEROTONIN;

AFFECTIVE NEUROSIS; CLINICAL TRIAL; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG SAFETY; HUMAN; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

EID: 0032916865     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979191     Document Type: Review

References (102)

1. Albuquerque EX, Eldefrawi AT, Eldefrawi ME, Mansour NA, Tsai MC: Amantadine: neuromuscular blockade by suppression of ionic conductance of the acetylcholine receptor. Science. 1978; 199: 788
2. Allen RM: Role of amantadine in the management of neuroleptic induced extrapyramidal syndromes: overview and pharmacology. Clin. Neuropharmacol. 1983; 6, Suppl. 1: S64-S73
3. Ambrozi L, Birkmayer W, Danielcyk E, Neumayer E, Riederer P: Biochemische Aspekte des menschlichen Verhaltens. Wien. Z. Nervenheilkd. Grenzgeb. 1973; 31: 191-215
4. Amsterdam JD, Winokur A, Dyson W, Herzog S, Gonzalez F, Rott R, Koprowski H: Borna disease virus: a possible etiologic factor in human affective disorders? Arch. Gen. Psychiatry. 1985; 42: 1093-1096
5. Ananth J, Ruskin R: Treatment of intractable depression. Int. Pharmacopsychiatry 1974; 9: 4: 218-229
6. Bailey EV, Stone TW: The mechanism of action of amantadine in Parkinsonism: a review. Arch. Int. Pharmacodyn. 1975; 216: 246-262
7. Baldessarini RJ, Lipinski JF, Chace KV: Effects of amantadine hydrochloride on catecholamine metabolism in the brain of the rat. Biochem. Pharmacol. 1972; 21: 77-87
8. Balogh S, Hendricks SE, Kang J: Treatment of fluoxetine-induced anorgasmia with amantadine. J. Clin. Psychiatry 1992; 53; 6: 212-213
9. Balon R: Intermittent amantadine for fluoxetine-induced anorgasmia. J. Sex. Marital Ther. 1996; 22; 4: 290-292
10. Ban TA: The use of amphetamines in adult psychiatry. Semin. Psychiatry 1969; 1; 2: 129-143
11. Bechter K, Herzog S, Schüttler R: Possible significance of Borna disease for humans. Neurol. Psychiatry Brain Res. 1992; 1: 23-29
12. Bechter K, Herzog S, Schüttler R: Borna disease virus - possible cause of human neuropsychiatric disorders. Neurol. Psychiatry Brain Res. 1996; 4: 45-52
13. Bode L, Zimmermann W, Ferszt R, Steinbach F, Ludwig H: Borna disease virus genome transcribed and expressed in psychiatric patients. Nature Med. 1995; 1; 3: 232-236
14. Bode L, Dürrwald R, Rantam FA, Ferszt R, Ludwig H: First isolates of infectious human Borna disease virus from patients with mood disorders. Mol. Psychiatry 1996; 1: 200-212
15. Bode L, Dietrich DE, Stoyloff R, Emrich HM, Ludwig H: Amantadin and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet 1997; 349: 178-179
16. Bormann J: Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 1989; 166: 591-592
17. Bryson YJ, Monahan C, Pollack M, Shields WD: A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis. J. Infect. Dis. 1980; 141; 5: 543-547
18. Chopra YM, Dandiya PC: Potentiation of anticatatonic effect of antidepressants by amantadine. Indian J. Med. Res. 1977; 66; 1: 142-149
19. Cohen RA, Fisher M: Amantadine treatment of fatigue associated with multiple sclerosis. Arch. Neurol. 1989; 46: 676-680
20. Couch RB, Jackson GG: Antiviral agents in influenza. Summary of Influenza Workshop VIII. J. Infect. Dis. 1976; 134: 516-527
21. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G: Aminoadamentanes as NMDA receptor antagonists and anti-parkinsonian agents: preclinical studies. Neurosci. Biobehav. Rev. 1997; 121; 4: 455-468
22. Davies JA, Jackson B, Redfern PH: The effect of amantadine, L-dopa, (+)-amphetamine and apomorphine on the acquisition of the conditioned avoidance response. Neuropharmacology 1974; 13: 199-204
23. Davies WL, Grunert RR, Haff RF, McGahen JW, Neumayer EM, Paulshock M, Watts JC, Wood TR, Hermann EC Hoffmann CE: Antiviral activity of 1-adamantanamine (amantadine). Science 1964; 144: 862-863
24. Di Chiara G, Morelli M, Consolo S: Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci. 1994; 17: 228-233
25. Dietrich DE, Bode L, Ludwig H, Spannhuth C, Emrich HM: Therapeutische Implikationen der Borna Disease Virus (BDV)-Infektion bei affektiven Psychosen. Psychiatrie als Therapiefach, ed. A. Mameros and P. Brieger. Regensburg: S. Roderer Verlag 1997
26. DiMascio A, Bernardo DL, Greenblatt DJ, Marder JE: A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch. Gen. Psychiatry 1976; 33: 599-602
27. Erkulwater S, Pillar R: Amantadine and the end-stage dementia of Alzheimer's type. South Med. J. 1989; 82: 550-554
28. Farnebo L-O, Fuxe K, Goldstein M, Hamberger B, Ungerstedt U: Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system: a possible mode of action in Parkinsons's disease. Eur. J. Pharmacol. 1971; 16: 27-38
29. Fibiger HC, Fox M, McGeer EG, McGeer PL: The effect of amantadine on spontaneous locomotor activity in the rat. J. Pharm. Pharmacol. 1971; 23: 724-725
30. Flaherty JA, Bellur SN: Mental side effects of amantadine therapy: its spectrum and characteristics in a normal population. J. Clin. Psychiatry 1981; 42: 344-345
31. Fletcher EA, Redfern PH: The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates. J. Pharm. Pharmacol. 1970; 22: 957-959
32. Fünfgeld EW: Amantadinwirkung bei Parkinsonismus. Dtsch Med Wochenschr 1970; 95: 1834-1836
33. Fünfgeld EW: Zweijährige Erfahrungen mit der Amantadintherapie bei Parkinsonismus. Ther. Woche 1972; 39: 3282-3299
34. Galbraith AW: Prevention of post-herpetic neuralgy by amantadine hydrochloride (Symmmetrel). Br. J. Clin. Pract. 1983; 37: 304-306
35. Gawin FH, Kleber HD, Byck R, Rounsaville BJ, Kosten TR, Jatlow PI, Morgan C: Desipramine facilitation of initial cocaine abstinence. Arch. Gen. Psychiatry 1989; 46: 117-121
36. Gianutsos G, Chute S, Dunn JP: Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. Eur. J. Pharmacol. 1985; 110: 357-361
37. Giannini AJ, Folts DJ, Feather JN, Sullivan BS: Bromocriptine and amantadine in cocaine detoxification. Psychiatry Res. 1989; 29: 11-16
38. Greenberg R, Meyers BS: Treatment of major depression and Parkinsons's disease with combined phenelzine and amantadine. Am. J. Psychiatry 1985; 142: 273-274
39. Grelak RP, Clark R, Stump JM, Vernier VG: Amantadine - dopamine interaction: possible role of action in Parkinsonism. Science 1970; 169: 203-204
40. Haacke U, Wesemann W: Zur Wirkung der 1-Aminoadamantane. Arzneim.-Forsch./Drug Res. 1977; 27; II; 7: 1481-1483
41. Halaris AE, Belendiuk KT, Freedman DX: Antidepressant drugs effect dopamine uptake. Biochem. Pharmacol. 1975; 24: 1869-1898
42. 3-dopamine in rat brain slices. Eur. J. Pharmacol. 1972; 20: 156-160
43. Henkel JG, Hane JT, Gianutsos G: Structure anti-Parkinson activity relationships in the aminoadamantanes: influence of bridgehead substitution. J. Med. Chem. 1982; 25: 51-56
44. Herblin WF: Amantadine and catecholamine uptake. Biochem. Pharmacol. 1972; 12: 1993-1995
45. Horn AS, Coyle JT, Snyder SH: Catecholamine uptake by synaptosomes from rat brain. Mol. Pharmacol. 1971; 7: 66-80
46. Jackson GG: Serological evidence for prevention of influenza infection in volunteers by an antiinfluenzal drug: adamantanamine hydrochlorid. Antimicrob. Agents Chemother. 1963; 3: 703-707
47. Jurna I, Grossmann T, Nell T: Depression by amantadine of drug-induced rigidity in the rat. Neuropharmacology 1972; 11: 559-564
48. Kadzielawa K: Dopamine receptor in the reward system of the rat. Arch. Int. Pharmacodyn. 1974; 209: 124-126
49. Kennedy A: The use of anti-depressive drugs. J. Ment. Sci. 1961; 107: 989-993
50. Kline NS: Drugs in the treatment of depressions: clinical studies. Psychiatric drugs, ed. P. Salomon. New York: Grune & Stratton 1966
51. Kolar AF, Brown BS, Weddington WW, Haertzen CC, Michaelson BS, Jaffe JH: Treatment of cocaine dependence in methadone maintenance clients: a pilot study comparing the efficacy of desipramine and amantadine. Int. J. Addict. 1992; 27; 7: 849-868
52. Kornhuber J, Streifler M: Adamantanamine. Neuro-Psychopharmaka, ed. P. Riederer, G. Laux and W. Pöldinger, 5: Parkinson-mittel und Nootropika. Vienna: 1992; Springer-Verlag: 59-76
53. 3HMK-801] at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 1989; 166: 589-590
54. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P: Effects of 1-aminoadamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur. J. Pharmacol. (Mol. Pharmacol. Sect.) 1991; 206: 297-300
55. Kosten TR, Morgan CH, Schottenfeld RS: Amantadine and desipramine in the treatment of cocaine abusing methadone maintained patients. NIDA research monograph. 1991; 105: 510-511
56. Kunzelmann V: Orale Kombinationstherapie der Zosterneuralgie. Fortschr. Med. 1993; 111: 423-425
57. Lang AE, Blair RDG: Anticholinergic drugs and amantadine in the treatment of Parkinson's disease. Handbook of experimental pharmacology, ed. DB. Calne. Springer, Berlin 1989; 88: 07-323
58. Lieb K, May G: Depression, Borna disease, and amantadine. Lancet 1997; 349: 958
59. Long WF, Olusanya J: Adamantanamine and early events following influenca virus infection. Arch. Ges. Virusforsch. 1972; 36: 18-22
60. Maj J, Sowinska H, Baran L: The effect of amantadine on motor activity and catalepsy in rats. Psychopharmacologia (Berl) 1972; 24: 296-307
61. Maj J, Sowinska H, Baran L, Sarnek J: Pharmacological effects of 1,3-dimethyl-5-amino-adamantane, a new adamantane derivate. Eur. J. Pharmacol. 1974; 26: 9-14
62. Masuo K, Enomoto K, Maeno T: Effects of memantine on the frog neuromuscular junction. Eur. J. Pharmacol. 1986; 130: 187-195
63. Miltner FO: Wertigkeit der symptomatischen Therapie mit Memantin beim zerebralen Koma. Arzneim. Forsch./Drug Res. 1982; 32: 1268-1270
64. Mindham RH, Marsden CD, Parkes JD: Psychiatric symptoms during L-dopa therapy for Parkinson's disease and their relationship to physical disability. Psychol. Med. 1976; 6: 23-33
65. Monto AS, Gunn RA, Bandyk MG, King CL: Prevention of Russian influenza by amantadine. JAMA 1979; 241: 1003-1007
66. Moryl E, Danysz W, Quack G: Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol. Toxicol. 1993; 72: 394-397
67. Mueller HF, Dastoor DP, Klingner A, Cole M, Boillat J: Amantadine in senile dementia: electroencephalographic and clinical effects. J. Am. Geriatr. Soc. 1979; 27: 9-16
68. Murray TJ: Amantadine therapy for fatigue in multiple sclerosis. Can. J. Neurol. Sci. 1985; 12: 251-254
69. Nastuk WL, Su PC, Doubilet P: Anticholinergic and membrane activities of amantadine in neuromuscular transmission. Nature 1976; 264: 76-79
70. Papeschi R: Amantadine may stimulate dopamine and noradrenaline receptors. Neuropharmacology. 1974; 13: 77-84
71. Parkes D: Amantadine. Adv. Drug Res. 1974; 8: 11-81
72. Parkes JD, Calver DM, Zilkha KJ, Knill-Jones RP: Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1970; 1: 259-262
73. Pita E, Perez N: Ultrastructural evidence of amantadine and amphetamine noradrenaline releasing action. Experientia 1976; 33/1: 72-74
74. Randrup A: Mania, depression and brain dopamine. Curr. Dev. Psychopharmacol. 1975; 2: 207-248
75. Randrup A, Mogilnicka E: Spectrum of pharmacological actions on brain dopamine: indications for development of new psychoactive drugs. Discussion of amantadines as examples of new drugs with special actions on dopamine systems. Pol. J. Pharmacol. Pharm. 1976; 28: 551-556
76. Rizzo M, Biandrate P, Tognoni G, Morselli PL: Amantadine in depression: relationship between behavioural effects and plasma levels Eur. J. Clin. Pharmacol. 1973; 5: 226-228
77. Roffler-Tarlov S: Differences between the effects of acute and long-term treatment with desmethylimipramine on reserpine-induced release of amines from rat brain. Biochem. Pharmacol. 1975; 24: 1321-1325
78. Rosenberg GA, Appenzeller D: Amantadine, fatigue and multiple sclerosis. Arch. Neurol. 1988; 45: 1104-1106
79. Rott R, Herzog S, Fleischer B, Winokur A, Amsterdam J, Dyson W, Koprowski H: Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders. Science 1985; 228: 755-756
80. Rott R, Herzog S, Bechter K, Frese K: Borna disease, a possible hazard for man? Arch. Virol. 1991; 118: 143-149
81. Scatton B, Cheramy A, Besson MJ, Glowinski J: Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur. J. Pharmacol. 1970; 13: 131-133
82. Schwab RS, England AC, Poskanzer DC, Young RR: Amantadine in the treatment of Parkinson's disease. JAMA 1969; 208: 1168-1170
83. Stein L: Effects and interactions of imipramine, chlorpromazine, reserpine and amphetamine on self-stimulation: possible neurophysiological basis of depression. Recent advances in biological psychiatry, ed. J. Wortis. New York: Plenum Press 1962: 188-309
84. Stone TW: Responses of neurones in the cerebral cortex and caudate nucleus to amantadine, amphetamine and dopamine. Br. J. Pharmacol. 1976; 1: 101-110
85. Stone TW, Bailey EV: Responses of central neurones to amantadine: comparison with dopamine and amphetamine. Brain Res. 1975; 85: 126-129
86. Strömberg U, Svensson TH, Waldeck B: The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates. J. Pharm. Pharmacol. 1970; 22: 957-962
87. Svensson TH, Strömberg U: Potentiation by amantadine hydrochloride of L-dopa-induced effects in mice. J. Pharm. Pharmacol. 1970; 22: 639-640
88. Svensson TH, Thieme G: An investigation of a new instrument to measure motor activity of small animals. Psychopharmacologie (Berl.). 1969; 14: 157-163
89. Tanaka C, Kimura M, Fujita Y, Shimada S: Effect of amantadine on serotonin metabolism in rat brain. Proceedings of the 46th General Meeting of the Japanese Pharmacological Society, Kumamoto. Jpn. J. Pharmacol. 1973; 23 (Suppl. 1): 125
90. Tennant F, Berman ML: Stepwise detoxification from cocaine. Postgrad. Med. 1988; 84; 2: 226-235
91. Tennant F, Sagherian AA: Double-blind comparison of amantadine and bromocriptine for ambulatory withdrawal from cocaine dependence. Arch. Intern. Med. 1987; 147; 1: 109-112
92. Thompson DF: Amantadine in the treatment of cocaine withdrawal. Ann. Pharmacother. 1992; 26: 933-934
93. Thornburg JE, Moore KE: A comparison of the locomotor stimulant properties of amantadine and L- and D-amphetamine in mice. Neuropharmacology 1972; 11: 675-682
94. Trullas R, Skolnick P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 1990; 185: 1-10
95. Trullas R, Folio T, Young A, Miller R, Boje K, Skolnick P: L-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur. J. Pharmacol. 1991; 203: 179-185
96. Vale S, Espejel MA, Dominguez JC: Amantadine in depression. Lancet 1971; 21: 437
97. Vernier VG, Harmon JB, Stump JM, Lynes TE, Marvel JP, Smith DH: The toxicologic and pharmacologic properties of amantadine hydrochloride. Tox. Appl. Pharmacol. 1969; 15: 642-665
98. Weddington WW, Brown BS, Haertzen CA, Hess JM, Kolar AF, Mahaffey JR: Comparison of amantadine and desipramine combined with psychotherapy for treatment of cocaine dependence. Probl. Drug Depend. 1989; 1: 483-484
99. Wesemann W, Ekenna O: Effect of L-aminoadamantanes on the MAO activity in brain, liver, and kidney of the rat. Arzneim.-Forsch./Drug Res. 1982; 32 (II); 10: 1241-1243
100. Wesemann W, Dette-Wildenhahn G, Fellehner H: In vitro studies on the possible effects of L-aminoadamantanes of the serotonergic system in M. Parkinson. J. Neural. Transm. 1979; 44: 263-285
101. Ziedonis DM, Kosten TR: Depression as a prognostic factor for pharmacological treatment of cocaine dependence. Psychopharmacol. Bull. 1991; 27; 3: 337-343
102. Ziedonis DM, Kosten TR: Pharmacotherapy improves treatment outcome in depressed cocaine addicts. J. Psychoact. Drugs. 1991; 23; 4: 417-425